Industry Projects
Our project area provides a repository of past, present and future projects within the industry. As well as providing an overview of the changing market landscape, this section offers access to the suppliers involved in each project.Latest Industry Projects
Provenge (sipuleucel-T) is an autologous cellular immunotherapy used intravenously in the form of infusion for the treatment of men with advanced prostate... > read more
Vyndaqel (Tafamidis) - Treatment for Transthyretin Familial Amyloid Polyneuropathy
Vyndaqel (tafamidis) is a first-in-class transthyretin stabiliser indicated for the treatment of Transthyretin Familial Amyloid Polyneuropathy...
Vyndaqel (tafamidis) is a first-in-class transthyretin stabiliser indicated for the treatment of Transthyretin Familial Amyloid Polyneuropathy...
Exparel for Postsurgical Pain Relief
Exparel is a non-opioid analgesic, developed to provide postsurgical pain relief. It is a long acting liposome injection of bupivacaine, a drug widely used to treat postsurgical...
Exparel is a non-opioid analgesic, developed to provide postsurgical pain relief. It is a long acting liposome injection of bupivacaine, a drug widely used to treat postsurgical...
Anacetrapib - Treatment for Atherosclerosis
Anacetrapib (MK-0859) is an orally active cholesteryl ester transfer protein (CETP) inhibitor indicated for the treatment of...
Anacetrapib (MK-0859) is an orally active cholesteryl ester transfer protein (CETP) inhibitor indicated for the treatment of...
Ivacaftor - Treatment for Cystic Fibrosis
Ivacaftor (VX-770) is a cystic fibrosis transmembrane conductor regulator (CFTR) potentiator indicated for the treatment of Cystic Fibrosis...
Ivacaftor (VX-770) is a cystic fibrosis transmembrane conductor regulator (CFTR) potentiator indicated for the treatment of Cystic Fibrosis...
Banzel – Treatment for Lennox-Gastaut syndrome
Banzel (Rufinamide) was developed in 2004 by Novartis Pharma. It is being manufactured by Eisai in Europe. It is indicated for the treatment of epileptic...
Banzel (Rufinamide) was developed in 2004 by Novartis Pharma. It is being manufactured by Eisai in Europe. It is indicated for the treatment of epileptic...
All Projects Alphabetically
- Abatacept - Treatment for Rheumatoid Arthritis
- Abiraterone
- ACE-031 for the Treatment of Duchenne Muscular Dystrophy, United States of America
- Acomplia (Rimonabant) - Investigational Agent for
- Actemra - Biological Therapy for Rheumatoid Arthritis
- Adcetris - Treatment for Relapsed or Refractory Hodgkin's Lymphoma
- Afamelanotide, Photo-Protective Drug
- Afinitor – Anti-Cancer Therapy
- Alemtuzumab – Potential in Multiple Sclerosis
- Almorexant
- AM103
- AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia, United Kingdom
- AN2728 for the Treatment of Psoriasis, United States of America
- Anacetrapib - Treatment for Atherosclerosis
- APD125 - Therapy for Insomnia
- Ariflo (Cilomilast) - Oral PDE-IV Inhibitor for
- ASA404 Vascular Disrupting Agent for Solid Tumours
- Avastin (bevacizumab) - Angiogenesis
- Axitinib – Treatment for Advanced Renal Cell Carcinoma
- Banzel – Treatment for Lennox-Gastaut syndrome
- Benlysta - Lupus Treatment
- BG-12 for the Treatment of Relapsing-Remitting Multiple Sclerosis, United States of America
- Bifeprunox - Atypical Antipsychotic Drug
- Blinatumomab
- BNC105
- Boceprevir
- Bosutinib - Chronic Myelogenous Leukaemia (CML) Treatment, United States of America
- Brilinta - Treatment for Acute Coronary Syndrome
- Byetta - First-in-Class Incretin Mimetic
- Caprospinol, Therapy for Alzheimer's Disease (AD)
- Ceftobiprole
- Celvapan – H1N1 Pandemic Influenza Vaccine
- Cepheid Xpert vanA Test Kit, United States of America
- Cerovive - Neuroprotectant for the
- Cervarix – Cervical Cancer Vaccine
- Cetilistat - Investigational Drug for Obesity
- Cilansetron - New Treatment for IBS
- Contrave for the Treatment of Obesity, United States of America
- Corifact – Treatment for Rare Form of Haemophilia
- Cuvposa - Treatment for Chronic Drooling
- CXL-1020 Treatment for Patients with Acute Decompensated Heart Failure (ADHF), United States of America
- Cymbalta (Duloxetine HCl) for Chronic Musculoskeletal Pain Management, United States of America
- Dalbavancin - Second-Generation Glycopeptide
- Daliresp (Roflumilast), Treatment to Reduce COPD, United States of America
- Darapladib - Selective Lp-PLA2 Inhibitor for Prevention of Atherosclerosis
- Dasatinib - Tyrosine Kinase Inhibitor for Chronic
- Dimebon - Investigational Compound Indicated for the Treatment of Alzheimer's and Huntington's Disease, United States of America
- Doripenem - A New Broad-Spectrum Carabapenem Antibiotic
- Edarbi for the Treatment of Hypertension, United States of America
- Edoxaban, Oral Anticoagulant, Japan
- Elacytarabine (CP-4055) for Treatment of Acute Myeloid Leukaemia, United States of America
- Elotuzumab
- Enbrel – Immunosuppressant for Treatment of Rheumatoid Arthritis
- Entecavir (Baraclude) - Oral Antiviral Drug for Hepatitis-B Infection, United States of America
- Erbitux (Cetuximab)
- ETC-216 - Phospholipid
- Exanta - Oral Direct Thrombin Inhibitor for the
- Exparel for Postsurgical Pain Relief
- Exubera - Inhaled Insulin
- Fablyn (Lasofoxifene) - Investigational SERM
- Fampridine-SR – Treatment for Multiple Sclerosis
- Dificid (fidaxomicin) – Narrow-Spectrum Antibiotic for Clostridium Difficile Infection
- Fingolimod - Novel Therapy for Multiple Sclerosis
- FIRAZYR – Treatment for Hereditary Angioedema
- Florbetaben
- Fludase - Experimental Antiviral Drug for Influenza
- FluLaval Influenza Virus Vaccine, United States of America
- Flurizan – Anti-Amyloid Drug for Treatment of Alzheimer’s Disease
- Idraparinux - Investigational Agent for Treatment and Prevention of Thromboembolic Events
- Iloperidone - Atypical Antipsychotic for Schizophrenia
- Iluvien, United States of America
- INCB9471 – CCR5 Antagonist for Treatment of HIV Infection
- Incivek / Telaprevir - Treatment for Chronic Hepatitis C
- Indinavir – First-Generation HIV Protease Inhibitor
- Influenza A (H1N1) Monovalent Vaccine by Sanofi Pasteur
- Inspra (Eplerenone)
- Intermezzo – Treatment for Insomnia, United States of America
- Istaroxime
- Ivacaftor - Treatment for Cystic Fibrosis
- Ixempra (Ixapebilone) – New Cancer Therapy
- Lamictal – Approved Treatment for Epilepsy and Bipolar, United States of America
- Latuda (lurasidone HCl) for the Treatment of Schizophrenia, United States of America
- Lexapro
- Licofelone - Novel Analgesic and Anti-Inflammatory
- Liraglutide - Next-Generation Antidiabetic Medication
- Lixisenatide
- LODOTRA - Treatment for Rheumatoid Arthritis
- Lorcaserin, Investigational Oral Anti-Obesity Drug
- Lurasidone - Treatment for Schizophrenia and Bipolar Disorder, Japan
- LY2140023 – Treatment of Schizophrenia
- Lyrica (Pregabalin) - New Gabapentinoid with Wide
- M6G, A New Morphine Derivative For Post-Operative Pain Relief
- Maraviroc - Therapy for Treatment of HIV Infection
- Menactra - Meningococcal Vaccine, United States of America
- Menveo vaccine for the prevention of invasive meningococcal disease, United States of America
- Merck Isentress - Emerging Therapy for Treatment of HIV Infection
- Mirapex (Pramipexole) - Treatment for Parkinson's Disease, Germany
- MOR103 - Antibody for the Treatment of Rheumatoid Arthritis, Germany
- Motavizumab - New Biological Therapy for RSV Prevention
- Multaq
- Mylinax - Novel Therapy for the Treatment of
- Nalmefene Treatment for Alcohol Dependence, Finland
- Naproxcinod (HCT 3012) - COX-Inhibiting Nitric Oxide-Donator
- Nexavar – Oral Anti-Cancer Agent for Treatment of Liver and Kidney Cancer
- Nexium I.V.- Treatment of Gastroesophageal Reflux Disease, United States of America
- NG2-73 - A Novel Agent For The Treatment of Insomnia
- NicVAX for Nicotine Addicition, United States of America
- Novavax Trivalent VLP Vaccine for Seasonal Influenza
- Nulojix - Treatment for Preventing Acute Organ Rejection Post Kidney Transplantation
- Pandemrix - Adjuvanted H1N1 Influenza Vaccine
- Panflu.1 – Single-Shot Vaccine Against H1N1 Influenza
- Paxil – SSRI for the Treatment of Major Depressive Disorders, United States of America
- Peginesatide (Hematide) – For the Treatment of Anaemia Associated with Chronic Kidney Disease
- Perampanel – Treatment for Epilepsy, Japan
- Pertuzumab – Cancer Therapy
- Phenserine - Next Generation AChE Inhibitor
- Pirfenidone – Treatment for Idiopathic Pulmonary Fibrosis
- Plectasin NZ2114 - Novel Microbial Agent
- Pradaxa – Oral Direct Thrombin Inhibitor
- Prasugrel - Investigational Antiplatelet Agent
- Prexige - COX-2 Inhibitor
- Prolia (Denosumab) - Therapy for Prevention and Treatment of Osteoporosis
- Provenge - Treatment for Advanced Prostate Cancer
- PSI-7977 for Treatment of Chronic Hepatitis C, United States of America
- Rapiacta (peramivir) - Neuraminidase Inhibitor for Treatment of Influenza
- Rasagiline - Second-Generation MAO-B Inhibitor
- Rasilez
- Rember
- Restanza
- Revatio (Sildenafil) - Treatment for Pulmonary Arterial Hypertension, United States of America
- Rezular – Oral Treatment for IBS
- Rifapentine
- Rituxan (Rituximab)
- Rupintrivir -
- Ruxolitinib - Treatment of Myelofibrosis, United States of America
- Sativex - Investigational Cannabis-Based treatment for Pain and Multiple Sclerosis
- Saxagliptin – Treatment for Type 2 Diabetes
- Semagacestat – Gamma Secretase Inhibitor for Alzheimer's Disease
- Seroquel - Treatment for Major Depressive Disorder (MDD)
- SF1126 -
- Soliris - Treatment for PNH and aHUS
- Stimuvax - Investigational Therapeutic Cancer Vaccine
- T-705 - Antiviral Drug for Influenza
- Tamiflu - Oral Anti-Viral Treatment Agent
- Taranabant
- Tarceva - Small Molecule
- Tasigna (Nilotinib), United States of America
- TB-402- Treatment of VTE and AF
- Telbivudine - Investigational Drug
- Tesmilifene - Chemopotentiator for Cancer
- Tofacitinib - Treatment for Rheumatoid Arthritis, United States of America
- Tradjenta - Treatment for Type II Diabetes
- TRA-SCH-530348
- Trastuzumab -, United States of America
- Treximet - Next-Generation Treatment for Migraine
- Trobalt / Potiga – Treatment for Partial-Onset Seizure
- Tygacil - Broad-Spectrum Antibiotic for Empiric
- Tykerb - Dual Tyrosine Kinase Inhibitor
- Tysabri - Therapeutic Monoclonal Antibody (MAb)
- V1512 - Treatment of Parkinson's Disease
- Valtorcitabine - Combination Drug Therapy for Chronic Hepatitis B
- Vesicare - Oral Selective Muscarinic Receptor
- Viibryd - Treatment for Major Depressive Disorder, United States of America
- Voreloxin, Anti-Cancer Quinolone Derivative, United States of America
- Vosaroxin - Treatment for Myeloid Leukaemia, United States of America
- Vyndaqel (Tafamidis) - Treatment for Transthyretin Familial Amyloid Polyneuropathy
- Xalkori - Treatment for Non-Small Cell Lung Cancer
- Xarelto - Investigational Agent for Treatment and Prevention of Thromboembolic Events
- Xeloda – Treatment for Metastatic Colorectal Cancer, United States of America
- Xgeva (Denosumab) for the Prevention of Metastatic Bone Cancer, United States of America
- Xiaflex to Treat Dupuytren's Contracture, United States of America
- XL184
- Xolair - Biological Therapy
- Zactima - Tyrosine Kinase Inhibitor
- Zegerid – Proton Pump Inhibitor for Treatment of Heartburn
- Zelboraf (vemurafenib) Tablets – Treatment for Metastatic Melanoma
- Zybrestat - Vascular Disrupting Agent and Cancer Therapy
- Zyprexa – Antipsychotic for the Treatment of Schizophrenia, Psychotic and Bipolar Disorders
